Lung Cancer Clinical Trial

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Summary

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.

View Full Description

Full Description

This aims to collect observational data that describe clinical (primary endpoint) and subclinical (secondary endpoint) cardiopulmonary toxicities from combined thoracic radiotherapy and immunotherapy up to 25 months after thoracic radiotherapy and 12 months after consolidation immunotherapy among patients with locally advanced lung cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient older than 18 years age

Diagnosis of locally advanced lung cancer (NSCLC or SCLC) with planned curative radiotherapy (45Gy and above) and planned consolidation immunotherapy.

Patients who are not receiving concurrent chemotherapy and radiotherapy are eligible.
Patients on a clinical trial that includes thoracic radiotherapy and immunotherapy are eligible and may be co-enrolled to this study.
ECOG performance status of 0-2
Life expectancy of 6 months or longer
Patient able to provide a written informed consent prior to study entry

Exclusion Criteria:

Prior thoracic radiotherapy to chest.
Patients are excluded if they are not candidates for curative thoracic radiotherapy or immunotherapy.
Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.

Study is for people with:

Lung Cancer

Estimated Enrollment:

125

Study ID:

NCT06410300

Recruitment Status:

Recruiting

Sponsor:

Bo Lu

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

University of Missouri - Ellis Fischel Cancer Center
Columbia Missouri, 65212, United States More Info
Bo Lu, MD
Principal Investigator
Gregory Biedermann, MD
Sub-Investigator
Ruobing Xue, MD
Sub-Investigator
Rutgers Cancer Institute of New Jersey
New Brunswick New Jersey, 08901, United States More Info
Salma Jabbour, MD
Principal Investigator
University of Rochester Medical Center
Rochester New York, 14642, United States More Info
Yuhchyau Chen, MD, PhD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

125

Study ID:

NCT06410300

Recruitment Status:

Recruiting

Sponsor:


Bo Lu

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.